Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML

Journal:
Blood
Published:
Affiliations:
17
Authors:
24
Institutions Authors Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)
6.333333
0.26
Montefiore Medical Center, Einstein, United States of America (USA)
5.500000
0.23
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), United States of America (USA)
2.000000
0.08
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
2.000000
0.08
Albert Einstein College of Medicine (Einstein), United States of America (USA)
1.500000
0.06
University of Florida (UF), United States of America (USA)
1.000000
0.04
Oxford MRC Weatherall Institute of Molecular Medicine (WIMM), United Kingdom (UK)
1.000000
0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
0.04
Oregon Health and Science University (OHSU), United States of America (USA)
1.000000
0.04
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, China
0.500000
0.02
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
0.500000
0.02
Broad Institute of MIT and Harvard, United States of America (USA)
0.500000
0.02
Shanghai General Hospital, SJTU, China
0.500000
0.02
Kings County Hospital, NYC Health and Hospitals, United States of America (USA)
0.333333
0.01
SUNY Downstate Health Sciences University (SUNY Downstate), United States of America (USA)
0.333333
0.01